Hongming Yu - Search Results

Year	Number of Results
2010	1
2014	1
2016	2
2019	1
2020	4
2021	3
2022	11
2023	9
2024	2

1

N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.

Wang J, Yu H, Dong W, Zhang C, Hu M, Ma W, Jiang X, Li H, Yang P, Xiang D. Wang J, et al. Among authors: yu h. Gastroenterology. 2023 May;164(6):990-1005. doi: 10.1053/j.gastro.2023.01.041. Epub 2023 Feb 8. Gastroenterology. 2023. PMID: 36764493 Free article.

2

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial.

Wang K, Xiang YJ, Yu HM, Cheng YQ, Liu ZH, Qin YY, Shi J, Guo WX, Lu CD, Zheng YX, Zhou FG, Yan ML, Zhou HK, Liang C, Zhang F, Wei WJ, Lau WY, Li JJ, Liu YF, Cheng SQ. Wang K, et al. Nat Med. 2024 Mar;30(3):708-715. doi: 10.1038/s41591-023-02786-7. Epub 2024 Jan 19. Nat Med. 2024. PMID: 38242982 Clinical Trial.

3

Calcium Scoring at Coronary CT Angiography Using Deep Learning.

Mu D, Bai J, Chen W, Yu H, Liang J, Yin K, Li H, Qing Z, He K, Yang HY, Zhang J, Yin Y, McLellan HW, Schoepf UJ, Zhang B. Mu D, et al. Among authors: yu h. Radiology. 2022 Feb;302(2):309-316. doi: 10.1148/radiol.2021211483. Epub 2021 Nov 23. Radiology. 2022. PMID: 34812674

4

Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study.

Wang K, Zhu H, Yu H, Cheng Y, Xiang Y, Cheng Z, Li Y, Li T, Wang D, Zhu Z, Cheng S. Wang K, et al. Among authors: yu h. J Oncol. 2023 Apr 15;2023:6353047. doi: 10.1155/2023/6353047. eCollection 2023. J Oncol. 2023. PMID: 37095751 Free PMC article.

5

Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma.

Xiang YJ, Wang K, Yu HM, Li XW, Cheng YQ, Wang WJ, Feng JK, Bo MH, Qin YY, Zheng YT, Shan YF, Zhou LP, Zhai J, Cheng SQ. Xiang YJ, et al. Hepatol Res. 2022 Aug;52(8):721-729. doi: 10.1111/hepr.13773. Epub 2022 May 22. Hepatol Res. 2022. PMID: 35536197

6

Gemcitabine and cisplatin or oxaliplatin chemotherapy combined with atezolizumab plus bevacizumab for advanced biliary tract cancers: a single-arm trial.

Wang K, Yu HM, Xiang YJ, Cheng YQ, Ni QZ, Guo WX, Shi J, Feng S, Zhai J, Cheng SQ. Wang K, et al. Future Oncol. 2023 May;19(15):1029-1035. doi: 10.2217/fon-2022-0189. Epub 2023 May 3. Future Oncol. 2023. PMID: 37132469

7

Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study.

Wang WJ, Liu ZH, Wang K, Yu HM, Cheng YQ, Xiang YJ, Feng JK, Zhou LP, Zhou HK, Pan WW, Guo WX, Shi J, Cheng SQ. Wang WJ, et al. Cancer Med. 2023 May;12(10):11513-11524. doi: 10.1002/cam4.5880. Epub 2023 Mar 31. Cancer Med. 2023. PMID: 36999793 Free PMC article.

8

Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study.

Wang K, Xiang YJ, Yu HM, Cheng YQ, Liu ZH, Zhong JY, Feng S, Ni QZ, Zhu HF, Pan WW, Li JJ, Liang C, Zhou HK, Meng Y, Lau WY, Cheng SQ. Wang K, et al. Front Immunol. 2023 Feb 16;14:1107542. doi: 10.3389/fimmu.2023.1107542. eCollection 2023. Front Immunol. 2023. PMID: 36875125 Free PMC article.

9

Pharmacist-led iodinated contrast media infusion risk assessment service.

Jiang H, Li Y, Wu X, Yu H, Zhang X, Ge W, Yan S. Jiang H, et al. Among authors: yu h. Front Pharmacol. 2023 May 9;14:1161621. doi: 10.3389/fphar.2023.1161621. eCollection 2023. Front Pharmacol. 2023. PMID: 37229268 Free PMC article.

10

Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase II trial.

Wang K, Yu HM, Xiang YJ, Cheng YQ, Ni QZ, Guo WX, Shi J, Feng S, Zhai J, Cheng SQ. Wang K, et al. Future Oncol. 2022 Sep;18(30):3367-3375. doi: 10.2217/fon-2022-0188. Epub 2022 Aug 15. Future Oncol. 2022. PMID: 35968836

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

32 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year